Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377972 | 0.76 | HSD11B1 (0.35) | HSD11B1KMT2ACCR1RAB9ACCR5 | |
| SCHEMBL4875426 | 0.74 | DRD3 (0.43) | DRD2DRD3KCNH2 | |
| SCHEMBL13049797 | 0.74 | PDE10A (0.41) | HSD11B1DRD2DRD3KCNH2 | |
| SCHEMBL10942013 | 0.71 | HSD11B1 (0.76) | HSD11B1KDM4EALDH1A1RAB9A | |
| SCHEMBL23465977 | 0.69 | NPC1 (0.60) | DRD2DRD3KCNH2ALDH1A1GAA | |
| SCHEMBL4877877 | 0.69 | CYP1A2 (0.46) | HSD11B1DRD2DRD3KCNH2KDM4E | |
| SCHEMBL17712726 | 0.68 | DRD3 (0.48) | DRD2DRD3KCNH2ALDH1A1GAA | |
| SCHEMBL14420292 | 0.68 | CCR1 (0.37) | HSD11B1KDM4EALDH1A1KMT2ACCR1 | |
| SCHEMBL8628370 | 0.68 | HSD11B1 (0.46) | HSD11B1KDM4EALDH1A1GLAGAA | |
| SCHEMBL1544072 | 0.68 | HSD11B1 (0.55) | HSD11B1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-10239870-B2 | Dopamine D3 receptor antagonists | INDIVIOR UK LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-10239870-B2 | Dopamine D3 receptor antagonists | INDIVIOR UK LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | INDIVIOR UK LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282318-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS | DRD3, DRD2, DRD4 | HSD11B1 2057/4885DRD2 2/4885DRD3 1/4885 |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | HSD11B1 2060/4885DRD2 2/4885DRD3 1/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | HSD11B1 2060/4885DRD2 2/4885DRD3 1/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | HSD11B1 2060/4885DRD2 2/4885DRD3 1/4885 |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | HSD11B1 2060/4885DRD2 2/4885DRD3 1/4885 |
| US-10239870-B2 | Dopamine D3 receptor antagonists | DRD3, DRD2, DRD4 | HSD11B1 2057/4885DRD2 2/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.